key: cord-0843158-2emukylv
authors: Pahalyants, Vartan; Murphy, William S.; Klebanov, Nikolai; Lu, Chen; Theodosakis, Nicholas; Klevens, R. Monina; Estiri, Hossein; Lilly, Evelyn; Asgari, Maryam; Semenov, Yevgeniy R.
title: Reply to: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated
date: 2022-03-29
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2022.03.042
sha: ed9b81d2bb05d19c57ac6752f12423f64b0491ab
doc_id: 843158
cord_uid: 2emukylv

nan

propose a personalized vaccination schedule to address COVID-19 susceptibility among patients 42 with immune-mediated inflammatory diseases treated with rituximab, which may blunt the 43 humoral immune response to the COVID-19 vaccine. 1 In their manuscript, the authors cite 44 mounting evidence of higher risk for infection among rituximab-treated patients and raise 45 concerns that our study was underpowered to detect this risk and did not account for behavior 46 modifications among these vulnerable patients.

To address these concerns, we emphasize that our study was a unique matched study comparing 

COVID-19 vaccination in IMID patients